Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Revaccination in Subsequent Pregnancies
NCT06866405Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Apr 2025; status: recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06866405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866405.